Advertisement
Australia markets closed

  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     

  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     

  • AUD/USD

    0.6604
    -0.0017 (-0.26%)
     

  • OIL

    78.20
    -1.06 (-1.34%)
     

  • GOLD

    2,366.90
    +26.60 (+1.14%)
     

  • Bitcoin AUD

    92,097.40
    -3,083.74 (-3.24%)
     

  • CMC Crypto 200

    1,261.38
    -96.63 (-7.12%)
     

  • AUD/EUR

    0.6128
    -0.0010 (-0.16%)
     

  • AUD/NZD

    1.0963
    -0.0006 (-0.05%)
     

  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     

  • NASDAQ

    18,161.18
    +47.72 (+0.26%)
     

  • FTSE

    8,433.76
    +52.41 (+0.63%)
     

  • Dow Jones

    39,512.84
    +125.08 (+0.32%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

Company News for June 2, 2020

Zacks Equity Research
·1-min read

  • Shares of Myovant Sciences Ltd. MYOV jumped 38.2% after the company submitted New Drug Application to the FDA for treatment of women with uterine fibroids.

  • Shares of Iterum Therapeutics plc ITRM plunged 59.6% after the company reported topline results for a Phase 3 clinical trial of oral and IV sulopenem in complicated urinary tract infection.

  • Shares of Coty Inc. COTY soared 20.9% after the company announced that KKR plans to acquire 60% of Coty's professional and retail hair business for $2.5 billion as a part of strategic transformation.

  • Shares of OPKO Health, Inc. OPK rose 6.1% after the company reported that it was authorized by the FDA for a trial evaluating RAYALDEE in coronavirus patients.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
OPKO Health, Inc. (OPK) : Free Stock Analysis Report
 
Coty Inc. (COTY) : Free Stock Analysis Report
 
Myovant Sciences Ltd. (MYOV) : Free Stock Analysis Report
 
Iterum Therapeutics PLC (ITRM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.